The Lancet Oncology: January 25, 2013

The Lancet Oncology in conversation with - A podcast by The Lancet Group

Categories:

Education

John Farley discusses a trial of the MEK inhibitor selumetinib for the treatement of low-grade serous carcinoma of the ovary and peritoneum. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv